menu
    • menu
    [{"orgOrder":0,"company":"Glox Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Glox Therapeutics Secures \u00a34.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Engineered Protein Bacteriocin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Glox Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Glox Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Glox Therapeutics \/ Boehringer Ingelheim Venture Fund"}]

    Find Clinical Drug Pipeline Developments & Deals by Glox Therapeutics

    Menu

    Glox Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glox Therapeutics

                            United Kingdom arrow
                            FNCE 2024
                            Not Confirmed

                            Glox Therapeutics

                            United Kingdom arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Protein Bacteriocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Boehringer Ingelheim Venture Fund

                            Deal Size : $5.4 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bac...

                            Details : The Company will use the funding to accelerate its bacteriocin development programme utilising engineered protein bacteriocins, which exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 13, 2023

                            Lead Product(s) : Engineered Protein Bacteriocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Boehringer Ingelheim Venture Fund

                            Deal Size : $5.4 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth